ASTRO's Framework for Radiopharmaceutical Therapy Curriculum Development for Trainees

被引:11
|
作者
Kiess, Ana P. [1 ]
Hobbs, Robert F. [1 ]
Bednarz, Bryan [2 ]
Knox, Susan J. [3 ]
Meredith, Ruby [4 ]
Escorcia, Freddy E. [5 ]
机构
[1] Johns Hopkins Univ, Dept Radiat Oncol, Baltimore, MD 21218 USA
[2] Univ Wisconsin Madison, Dept Med Phys, Madison, WI USA
[3] Stanford Univ, Dept Radiat Oncol, Med Ctr, Stanford, CA USA
[4] Univ Alabama Birmingham, Comprehens Canc Ctr, Dept Radiat Oncol, Birmingham, AL USA
[5] NCI, NIH, Ctr Canc Res, Mol Imaging Branch, Bethesda, MD USA
关键词
RESISTANT PROSTATE-CANCER; HEPATOCELLULAR-CARCINOMA; NEUROENDOCRINE TUMORS; OPEN-LABEL; DOSIMETRY; RADIOEMBOLIZATION; RADIOBIOLOGY; RADIUM-223; RADIATION; THERANOSTICS;
D O I
10.1016/j.ijrobp.2022.03.018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In 2017, the American Society for Radiation Oncology (ASTRO) board of directors prioritized radiopharmaceutical therapy (RPT) as a leading area for new therapeutic development, and the ASTRO RPT workgroup was created. Herein, the work -group has developed a framework for RPT curriculum development upon which education leaders can build to integrate this modality into radiation oncology resident education. Through this effort, the workgroup aims to provide a guide to ensure robust training in an emerging therapeutic area within the context of existing radiation oncology training in radiation biology, medical physics, and clinical radiation oncology. The framework first determines the core RPT knowledge required to select patients, prescribe, safely administer, and manage related adverse events. Then, it defines the most important topics for preparing residents for clinical RPT planning and delivery. This framework is designed as a tool to supplement the cur-rent training that exists for radiation oncology residents. The final document was approved by the ASTRO board of directors in the fall of 2021. (C) 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:719 / 726
页数:8
相关论文
共 50 条
  • [1] European Association of Nuclear Medicine (EANM) response to the proposed ASTRO's framework for radiopharmaceutical therapy curriculum development for trainees
    Dierckx, Rudi
    Herrmann, Ken
    Hustinx, Roland
    Lassman, Michael
    Wadsak, Wolfgang
    Kunikowska, Jolanta
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 50 (01) : 1 - 3
  • [2] European Association of Nuclear Medicine (EANM) response to the proposed ASTRO’s framework for radiopharmaceutical therapy curriculum development for trainees
    Rudi Dierckx
    Ken Herrmann
    Roland Hustinx
    Michael Lassmann
    Wolfgang Wadsak
    Jolanta Kunikowska
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 50 : 1 - 3
  • [3] Correction to: European Association of Nuclear Medicine (EANM) response to the proposed ASTRO’s framework for radiopharmaceutical therapy curriculum development for trainees
    Rudi Dierckx
    Ken Herrmann
    Roland Hustinx
    Michael Lassmann
    Wolfgang Wadsak
    Jolanta Kunikowska
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 630 - 630
  • [4] Letter to Editor for "European Association of Nuclear Medicine (EANM) response to the proposed ASTRO's framework for radiopharmaceutical therapy curriculum development for trainees."
    Bashir, Humayun
    Younis, Muhammad Numair
    Naseer, Hamid
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (03) : 648 - 649
  • [5] Letter to Editor for “European Association of Nuclear Medicine (EANM) response to the proposed ASTRO’s framework for radiopharmaceutical therapy curriculum development for trainees.”
    Humayun Bashir
    Muhammad Numair Younis
    Hamid Naseer
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 648 - 649
  • [6] European Association of Nuclear Medicine (EANM) response to the proposed ASTRO's framework for radiopharmaceutical therapy curriculum development for trainees (Nov, 10.1007/s00259-022-06011-4, 2022)
    Dierckx, Rudi
    Herrmann, Ken
    Hustinx, Roland
    Lassmann, Michael
    Wadsak, Wolfgang
    Kunikowska, Jolanta
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (02) : 630 - 630
  • [7] A Framework for Patient-Centered Pathways of Care for Radiopharmaceutical Therapy: An ASTRO Consensus Document
    Buatti, John M.
    Pryma, Daniel A.
    Kiess, Ana P.
    Mailman, Josh
    Ennis, Ronald D.
    Menda, Yusuf
    White, Gerald A.
    Pandit-Taskar, Neeta
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 109 (04): : 913 - 922
  • [8] ACR-ASTRO Practice Guideline for the Performance of Therapy With Unsealed Radiopharmaceutical Sources
    Henkin, Robert E.
    Del Rowe, John D.
    Grigsby, Perry W.
    Hartford, Alan C.
    Jadvar, Hossein
    Macklis, Roger M.
    Parker, J. Anthony
    Wong, Jeffrey Y. C.
    Rosenthal, Seth A.
    CLINICAL NUCLEAR MEDICINE, 2011, 36 (08) : E72 - E80
  • [9] ASTRO's core physics curriculum for radiation oncology residents
    Klein, EE
    Balter, JM
    Chaney, EL
    Gerbi, BJ
    Hughes, L
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (03): : 697 - 705
  • [10] Modeling Combined Radiopharmaceutical Therapy: A Linear Optimization Framework
    Besse, Ian M.
    Madsen, Mark T.
    Bushnell, David L.
    Juweid, Malik E.
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2009, 8 (01) : 51 - 60